206 related articles for article (PubMed ID: 35730519)
21. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
22. KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.
Mühlenberg T; Falkenhorst J; Schulz T; Fletcher BS; Teuber A; Krzeciesa D; Klooster I; Lundberg M; Wilson L; Lategahn J; von Mehren M; Grunewald S; Tüns AI; Wardelmann E; Sicklick JK; Brahmi M; Serrano C; Schildhaus HU; Sievers S; Treckmann J; Heinrich MC; Raut CP; Ou WB; Marino-Enriquez A; George S; Rauh D; Fletcher JA; Bauer S
J Clin Oncol; 2024 Apr; 42(12):1439-1449. PubMed ID: 38408285
[TBL] [Abstract][Full Text] [Related]
23. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
Zook P; Pathak HB; Belinsky MG; Gersz L; Devarajan K; Zhou Y; Godwin AK; von Mehren M; Rink L
Clin Cancer Res; 2017 Jan; 23(1):171-180. PubMed ID: 27370604
[TBL] [Abstract][Full Text] [Related]
24. The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.
Schaefer IM; DeMatteo RP; Serrano C
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35522913
[TBL] [Abstract][Full Text] [Related]
25. TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors.
Khosroyani HM; Klug LR; Heinrich MC
Drugs; 2023 Jan; 83(1):55-73. PubMed ID: 36607590
[TBL] [Abstract][Full Text] [Related]
26. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
27. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
Senchak J; Ahr K; von Mehren M
Curr Treat Options Oncol; 2022 May; 23(5):749-761. PubMed ID: 35349049
[TBL] [Abstract][Full Text] [Related]
28. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
29. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
30. [New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy].
Lemaître J; Watson S
Bull Cancer; 2022 Mar; 109(3):250-252. PubMed ID: 35094842
[No Abstract] [Full Text] [Related]
31. Gastrointestinal stromal tumor: a review of current and emerging therapies.
Al-Share B; Alloghbi A; Al Hallak MN; Uddin H; Azmi A; Mohammad RM; Kim SH; Shields AF; Philip PA
Cancer Metastasis Rev; 2021 Jun; 40(2):625-641. PubMed ID: 33876372
[TBL] [Abstract][Full Text] [Related]
32. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.
Gounder MM; Maki RG
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Serrano C; García-Del-Muro X; Valverde C; Sebio A; Durán J; Manzano A; Pajares I; Hindi N; Landolfi S; Jiménez L; Rubió-Casadevall J; Estival A; Lavernia J; Safont MJ; Pericay C; Díaz-Beveridge R; Martínez-Marín V; Vicente-Baz D; Vivancos A; Hernández-Losa J; Arribas J; Carles J
Oncologist; 2019 May; 24(5):680-687. PubMed ID: 30126859
[TBL] [Abstract][Full Text] [Related]
34. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
35. Emerging drugs for the treatment of gastrointestinal stromal tumour.
Kasireddy V; von Mehren M
Expert Opin Emerg Drugs; 2017 Dec; 22(4):317-329. PubMed ID: 29183145
[TBL] [Abstract][Full Text] [Related]
36. Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2.
Zhao Y; Weng Z; Zhou X; Xu Z; Cao B; Wang B; Li J
J Transl Med; 2023 Mar; 21(1):219. PubMed ID: 36966336
[TBL] [Abstract][Full Text] [Related]
37. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
Gao X; Xue A; Fang Y; Shu P; Ling J; Hou Y; Shen K; Qin J; Sun Y; Qin X
Oncotarget; 2016 Mar; 7(12):14300-9. PubMed ID: 26893362
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
39. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
Schuetze SM; Bolejack V; Thomas DG; von Mehren M; Patel S; Samuels B; Choy E; D'Amato G; Staddon AP; Ganjoo KN; Chow WA; Rushing DA; Forscher CA; Priebat DA; Loeb DM; Chugh R; Okuno S; Reinke DK; Baker LH
JAMA Oncol; 2018 Jun; 4(6):814-820. PubMed ID: 29710216
[TBL] [Abstract][Full Text] [Related]
40. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
